3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Breast Neoplasms
31
Neoplasms
8
Endometrial Neoplasms
6
Neoplasm Metastasis
5
Brain Neoplasms
5
Triple Negative Breast Neoplasms
4
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Head and Neck Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Meningioma
3
Glioblastoma
3
Sarcoma
2
Pancreatic Neoplasms
2
Oligodendroglioma
2
Lymphoma, Non-Hodgkin
2
Carcinoma, Non-Small-Cell Lung
2
Urologic Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Spinal Cord Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Retinoblastoma
1
Recurrence
1
Pathologic Complete Response
1
Osteosarcoma
1
Neoplasms, Squamous Cell
1
Neoplasm, Residual
1
Multiple Myeloma
1
Interventions
Cisplatin
66
Paclitaxel
43
Radiotherapy
39
Carboplatin
29
Fluorouracil
27
Drug Therapy
20
Irinotecan
16
toripalimab
15
pembrolizumab
15
tislelizumab
14
camrelizumab
13
sintilimab
12
Radiotherapy, Intensity-Modulated
11
Albumin-Bound Paclitaxel
11
S 1 (combination)
10
Capecitabine
10
130-nm albumin-bound paclitaxel
10
apatinib
9
Radiation
9
Oxaliplatin
9
Neoadjuvant Therapy
9
Esophagectomy
9
Docetaxel
9
nimotuzumab
8
TP protocol
8
Cetuximab
8
anlotinib
7
Nivolumab
7
nedaplatin
6
Taxes
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Esophageal Squamous Cell Carcinoma
×
abemaciclib
×
Clear all
NCT03339843
2024-03-15
MiMe-A
Jules Bordet Institute
Phase 2
Completed
85 enrolled